TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1576071

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (1 g three times daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg three times daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3930128

Group type: EXPERIMENTAL
Intervention: 0.25 unit/h aVP infusion
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1.0 unit/h aVP infusion
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2.0 unit/h aVP infusion
Number of subjects: 4
Study: 30939213

Group type: EXPERIMENTAL
Intervention: Na control (individually and automatically adjusted dialysate sodium concentration)
Number of subjects: 31

Group type: COMPARATOR
Intervention: standard fixed Na (fixed dialysate sodium 138 mmol/L)
Number of subjects: 31
Study: 29493395

Group type: EXPERIMENTAL
Intervention: Topical azithromycin 15 mg/g ophthalmic solution, used twice a day for 3 days and then once a day until treatment completion (1 month).
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral azithromycin 250 mg tablets, 1×2 tablets (500 mg) on the first day, then 1×1 tablet (250 mg) for 4 days, with 3 cycles of treatment and 5-day intervals.
Number of subjects: 30
Study: 28639865

Group type: EXPERIMENTAL
Intervention: Sumac juice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24671897

Group type: EXPERIMENTAL
Intervention: Daily monitored device-based parameters (heart rate, thoracic impedance, HR variability, physical activity)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of HR and TI with LVEF and NT-proBNP
Number of subjects: 96
Study: 22545373

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study: 20182456

Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide combination (320/25 mg)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Valsartan (320 mg)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 675
Study: 18625166

Group type: EXPERIMENTAL
Intervention: Physician recommendation for CRC screening
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Educational materials (videotapes, written materials)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Frank and informative dialogue about patient's concerns
Number of subjects: 15
Study: 15704683

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate supplement in Group I (n = 25)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No intervention in Group II (n = 39)
Number of subjects: 64
Study: 11809596

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide/erythromycin combination (BP/E)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Benzoyl peroxide (BP)
Number of subjects: 40
Study: 10366088

Group type: EXPERIMENTAL
Intervention: 1 DEX DDS (60 microg dexamethasone)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2 DEX DDS (60 microg dexamethasone)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo DDS (no active drug)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DEX DDS (1 or 2 doses)
Number of subjects: 90
Study: 7746691

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (n = 21), administered twice daily for 2 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 19), administered twice daily for 2 days
Number of subjects: 40
Study: 1791611

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 32
Study: 7272145

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg and Diazepam 5 mg (combination)
Number of subjects: 105
Study: 31943693

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB; Cardionovum, Bonn, Germany)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Drug-eluting stent (DES; Medtronic, Minneapolis, Minnesota)
Number of subjects: 230
Study: 30875487

Group type: EXPERIMENTAL
Intervention: HD-MTX
Number of subjects: 566

Group type: COMPARATOR
Intervention: C-MTX
Number of subjects: 566
Study: 28444178

Group type: EXPERIMENTAL
Intervention: Hybrid procedure (coronary artery bypass grafting performed on the beating heart with cardiopulmonary bypass support followed by cardioplegic arrest for the valve procedure)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional procedure (both procedures under cardioplegic arrest)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Hybrid procedure
Number of subjects: 160
Study: 25311934

Group type: EXPERIMENTAL
Intervention: mannose 6‐phosphate
Number of subjects: 39

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 39
Study: 23920048

Group type: EXPERIMENTAL
Intervention: 0.25 mg of GnRH antagonist daily for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard flexible GnRH antagonist protocol
Number of subjects: 30
Study: 19706697

Group type: EXPERIMENTAL
Intervention: Quetiapine (n = 16)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Olanzapine (n = 16)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 50
Study: 19210631

Group type: EXPERIMENTAL
Intervention: Ghrelin (40 microg) administered i.v. over 30 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo) administered i.v. over 30 min
Number of subjects: 10
Study: 16770138

Group type: EXPERIMENTAL
Intervention: Dr. Brown's Natural Flow Baby Bottles
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo bottles
Number of subjects: 36
Study: 12768356

Group type: EXPERIMENTAL
Intervention: Oral administration of 200 mg levodopa (LD)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Subcutaneous injection of 4 mg apomorphine (A)
Number of subjects: 2
Study: 10770815

Group type: EXPERIMENTAL
Intervention: CT scan before FOB (Group A)
Number of subjects: 171

Group type: COMPARATOR
Intervention: FOB without prior CT scan (Group B)
Number of subjects: 171
Study: 9327093

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (NTX) 2 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: SIB episode
Number of subjects: 10
Study: 8222031

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia with N2O (P/N2O)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia without N2O (P/O2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Thiopentone and halothane anaesthesia (T/H)
Number of subjects: 75
Study: 3950252

Group type: EXPERIMENTAL
Intervention: Cat allergen treatment (15 with cat allergen)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Dog allergen treatment (7 with dog allergen)
Number of subjects: 41
Study: 30920245

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for seasonal affective disorder (CBT-SAD)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Light therapy
Number of subjects: 177
Study: 29885168

Group type: EXPERIMENTAL
Intervention: Myrtus communis L. solution
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ketoconazole shampoo
Number of subjects: 90
Study: 27103548

Group type: EXPERIMENTAL
Intervention: Yoga intervention (2× weekly yoga classes for 12 weeks, complemented by regular home practice guided by a manual)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Delayed treatment group (control)
Number of subjects: 144
Study: 24647274

Group type: EXPERIMENTAL
Intervention: Patient Advocate Crisis Plan (PACP)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Clinician-facilitated Crisis Plan (CCP)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control
Number of subjects: 212
Study: 22647089

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (6 mg · kg⁻¹ body-mass)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20096897

Group type: EXPERIMENTAL
Intervention: Soy food-containing diet with 10 g/d prebiotic (oligofructose-enriched inulin)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Prebiotic (10 g/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Soy food-containing diet (30 g/d soy protein, 61 mg/d isoflavones) with 10 g/d placebo (maltodextrin)
Number of subjects: 23
Study: 18029465

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg/d) plus exercise training (endurance and resistance)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Exercise training (endurance and resistance)
Number of subjects: 31
Study: 15910512

Group type: EXPERIMENTAL
Intervention: AR-R15896AR 120 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: AR-R15896AR 350 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12095664

Group type: COMPARATOR
Intervention: Methylphenidate 40 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atomoxetine 90 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Methylphenidate 20 mg and 40 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atomoxetine 20 mg, 45 mg, and 90 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16
Study: 12144191

Group type: EXPERIMENTAL
Intervention: Sleeve segmentectomy
Number of subjects: 8
Study: 9875081

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7531378

Group type: EXPERIMENTAL
Intervention: Jejunal J-pouch after gastrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Roux-en-Y pouch reconstruction
Number of subjects: 0
Study: 2786009

Group type: EXPERIMENTAL
Intervention: Nabumetone (2000 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aspirin (3.6 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 30
Study: 31384899

Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 114

Group type: COMPARATOR
Intervention: Delayed implant placement
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Flapless surgery
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: SLA and DAE surface treatment methods
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Graft procedure
Number of subjects: 114
Study: 28235974

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-19-36 amide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 26416653

Group type: EXPERIMENTAL
Intervention: simeprevir (SMV) in combination with pegylated interferon and ribavirin (PegIFN/R)
Number of subjects: 709

Group type: COMPARATOR
Intervention: telapravir (TVR) in combination with pegylated interferon and ribavirin (PegIFN/R)
Number of subjects: 709
Study: 24640205

Group type: EXPERIMENTAL
Intervention: Badriphal (Hippophae rhamnoides) 350 mg twice daily for 3 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 56
Study: 21194855

Group type: EXPERIMENTAL
Intervention: VLBW group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 37
Study: 17852127

Group type: EXPERIMENTAL
Intervention: Open-label stimulant medication
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unmedicated children with ADHD
Number of subjects: 36
Study: 16824073

Group type: EXPERIMENTAL
Intervention: CH100 (Chinese herbal therapy)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 14616189

Group type: EXPERIMENTAL
Intervention: Tiagabine 24 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tiagabine 12 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Active medications (Tiagabine 12 mg/day and 24 mg/day)
Number of subjects: 45
Study: 10853724

Group type: EXPERIMENTAL
Intervention: Follow-up visits with extensive testing and resultant measures after one month
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no follow-up visits)
Number of subjects: 95
Study: 9193755

Group type: EXPERIMENTAL
Intervention: Cytogenetic abnormalities detected at bone marrow harvest
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: ABMT (Autologous Bone Marrow Transplantation)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Conventional cytogenetic assessment
Number of subjects: 190
Study: 8466422

Group type: EXPERIMENTAL
Intervention: Exercise group (E) - resistance and balance training, 12 weeks, 3 times per week.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (C) - flexibility exercises performed sitting in a chair, 12 weeks, weekly meetings.
Number of subjects: 31
Study: 31786776

Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 117900

Group type: EXPERIMENTAL
Intervention: Glycoproteins
Number of subjects: 117900

Group type: EXPERIMENTAL
Intervention: LVLDLP
Number of subjects: 117900

Group type: EXPERIMENTAL
Intervention: MVLDLC
Number of subjects: 117900
Study: 31243035

Group type: EXPERIMENTAL
Intervention: Implementation of an evidence-based, goal-directed checklist for potential organ donor maintenance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care practices of the ICU
Number of subjects: 60
Study: 28573669

Group type: EXPERIMENTAL
Intervention: Consistent GWG tracking among not-low-income women
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Consistent GWG tracking among low-income women
Number of subjects: 898
Study: 26569501

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (reorganization of care by trained chronic care coaches, reminder systems, structured follow‐up, patient self‐monitoring, decision‐support)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 169

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 169
Study: 23838753

Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: ASPECTS M6 region interaction with age
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Lentiform nucleus interaction with age
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Blood sugar level interaction with age
Number of subjects: 607
Study: 21207091

Group type: COMPARATOR
Intervention: EAC (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, all b.i.d. for 8 days)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: EACL (EAC plus Lactobacillus acidophilus, 5 × 10(9) organisms per capsule, 3 + 2 i.d. for 8 days)
Number of subjects: 62
Study: 19327308

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham noninvasive ventilation (Control)
Number of subjects: 75
Study: 16963045

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound of the uterine arteries
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Fluorimetric immunoassays for free beta‐hCG and PAPP‐A
Number of subjects: 433
Study: 15577587

Group type: EXPERIMENTAL
Intervention: Post-injection transmission-based segmented attenuation correction (SAC) technique
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transmissionless calculated attenuation correction (CAC) technique
Number of subjects: 10
Study: 11323731

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (45mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9337763

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angioplasty and Coronary artery bypass surgery
Number of subjects: 0
Study: 7943831

Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms.kg-1
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 micrograms.kg-1
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (famotidine alone)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Clonidine (both doses)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 57
Study: 3034841

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus misonidazole
Number of subjects: 117

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 117
Study: 29731344

Group type: EXPERIMENTAL
Intervention: Baseline LCS score
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Symptom improvement (increase in LCS of two points or more during treatment)
Number of subjects: 327
Study: 26630942

Group type: EXPERIMENTAL
Intervention: Limb Remote Ischemic Conditioning (RIC) - four lower-limb conditioning sessions consisting of four 5-min cycles per session over nonconsecutive days.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (matched controls with aSAH).
Number of subjects: 82
Study: 24512953

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 146
Study: 23464930

Group type: EXPERIMENTAL
Intervention: Low-dose SPAA (5/10 or 10/10 mg)
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1461
Study: 20010119

Group type: EXPERIMENTAL
Intervention: Spirulina (6 g x d(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 17982749

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) program
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Strengthening exercise (SE) program
Number of subjects: 30
Study: 16860045

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) 150 mg/mL
Number of subjects: 608

Group type: COMPARATOR
Intervention: Nonhormonal contraception
Number of subjects: 608
Study: 14624371

Group type: EXPERIMENTAL
Intervention: CCR5-wt/Delta32 genotype
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: CCR5-wt/wt genotype with CCR5-59029-A/A variant
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: SDF1-3'-A/A variant
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: CCR5-59353, CCR5-59356, or CCR2 genotypes
Number of subjects: 1049
Study: 10760343

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonexercise Control
Number of subjects: 10
Study: 9010008

Group type: EXPERIMENTAL
Intervention: Suramin administered intravenously in escalating dosages (300, 350, and 400 micrograms ml-1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Suramin administered intravenously in escalating dosages (350 and 400 micrograms ml-1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Suramin administered intravenously with neurological monitoring
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Suramin with drug discontinuation and plasmapheresis
Number of subjects: 22
Study: 1509986

Group type: EXPERIMENTAL
Intervention: AM3 (glycophosphopeptide), 1 g daily for 4 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study: 6747061

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 53

Group type: COMPARATOR
Intervention: Diet plus exercise
Number of subjects: 53

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 53
Study: 30292481

Group type: EXPERIMENTAL
Intervention: Cocktail of 12 natural lytic anti‐Pseudomonas aeruginosa bacteriophages (PP1131; 1 × 106 PFU/mL) applied as a daily topical treatment for 7 days.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard of care (1% sulfadiazine silver emulsion cream) applied as a daily topical treatment for 7 days.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cocktail of 12 natural lytic anti‐Pseudomonas aeruginosa bacteriophages (PP1131).
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard of care (1% sulfadiazine silver emulsion cream).
Number of subjects: 27
Study: 27739232

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of 120 mg of ketorolac tromethamine over 24 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intramuscular bolus injections of 30 mg of ketorolac tromethamine every 6 hours (total daily dose of 120 mg)
Number of subjects: 12
Study: 26770927

Group type: EXPERIMENTAL
Intervention: Vitamin E therapy (n=58)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (n=58)
Number of subjects: 335
Study: 25127231

Group type: EXPERIMENTAL
Intervention: Neurostimulation (frequency 180 Hz; pulse width 120 μs; amplitude 0.5 V below adverse event threshold)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham stimulation (amplitude 0 V)
Number of subjects: 62
Study: 22489807

Group type: EXPERIMENTAL
Intervention: Active low-frequency electrical stimulation (2/100 Hz)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham (placebo) treatment
Number of subjects: 62
Study: 19156629

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 17592702

Group type: EXPERIMENTAL
Intervention: Custom-made orthoses
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Ready-made orthoses
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (no orthoses)
Number of subjects: 178
Study: 12765737

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11251350

Group type: EXPERIMENTAL
Intervention: Extended out‐of‐hospital prophylaxis with low‐molecular‐weight heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: A2 recommendation for extended prophylaxis
Number of subjects: 0
Study: 9299666

Group type: EXPERIMENTAL
Intervention: Favre system
Number of subjects: 14
Study: 8348279

Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone and lignocaine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lignocaine alone
Number of subjects: 55
Study: 3034021

Group type: EXPERIMENTAL
Intervention: 1.25 mg ramipril
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 2.5 mg ramipril
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All doses of ramipril
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (washout phase)
Number of subjects: 160